Objective The scientific goals of the proposed prom act are:1) To develop a array-array system to profile expression levels of drug metabolising enzymes after exposure of cell cultures or whole animals to xenobiotics (drugs or environmental compounds) and2) to develop an oligonucleotide-array system to detect variant alleles of genes that determine an individuals response to medicinal compounds (drugs) or determine an individuals risk on exposure to environmental toxins. Expression profiling of drug metabolising enzymes in animals and later in humans is a key component in the pre-clinical stages of new drug development in the pharmaceutical industry. Detection of variant alleles (genotyping), the second objective of the proposed collaboration, will address an emerging and far-reaching need in the pharmaceutical industry and in healthcare in general. The ultimate goal of this second objective is to develop a cost-effective method of pharmacogenetic profiling for use as a tool in clinical trial studies and in the longer term as a means of selecting the lost aoorioriate drug therapy for individual patients. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-3. - Key action The "Cell factory" Call for proposal Data not available Funding Scheme EAW - Exploratory awards Coordinator METABOLIC SYSTEMS CO EU contribution No data Address c/o Biochemistry Dept., Trinity College DUBLIN Ireland See on map Total cost No data Participants (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all AZIGN BIOSCIENCE A/S Denmark EU contribution No data Address Vestre Teglgade 10 2450 KOEPENHAGEN See on map Total cost No data
